Carmat Release: Professor Carpentier Finalist For The European Inventor Award 2016
CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced artificial
heart project, aiming to provide a therapeutic alternative for people suffering from end-stage
biventricular heart failure, announces that Professor Carpentier has been nominated as a finalist for
the European Inventor Award 2016.
This prestigious award is attributed by the European Patent Office (EPO) to scientists, researchers and engineers whose EPO-patented inventions have contributed to technological progress, social development and economic growth. 15 finalists have been shortlisted by an independent international jury from almost 400 inventors from 13 countries. Professor Carpentier is one of 3 finalists in the Lifetime Achievement category, and has been nominated for his work on the CARMAT artificial heart.
“We are delighted with this nomination for Professor Carpentier and for CARMAT. It again illustrates the Professor’s impressive scientific career and the amazing potential of the CARMAT prosthesis for patients suffering from end-stage heart failure, and highlights the Company’s economic development prospects in Europe and around the world”, says Jean-Claude Cadudal, Chairman of CARMAT.
About CARMAT: the world’s most advanced total artificial heart project
A credible response to end-stage heart failure: CARMAT aims to eventually provide a response to a major public health issue associated with heart disease, the world’s leading cause of death: chronic and acute heart failure. By pursuing the development of its total artificial heart, CARMAT intends to overcome the well-known shortfall in heart transplants for the tens of thousands of people suffering from irreversible end-stage heart failure, the most seriously affected of the 20 million patients with this progressive disease in Europe and the United States.
The result of combining two types of unique expertise: the medical expertise of Professor Carpentier, known throughout the world for inventing Carpentier-Edwards® heart valves, which are the most used in the world, and the technological expertise of Airbus Group, world aerospace leader.
Imitating the natural heart: given its size, the choice of structural materials and its innovative physiological functions, CARMAT’s total artificial heart could, assuming the necessary clinical trials are successful, potentially benefit the lives of thousands of patients a year with no risk of rejection and with a good quality of life.
A project leader acknowledged at a European level: with the backing of the European Commission, CARMAT has been granted the largest subsidy ever given to an SME by Bpifrance; a total of €33 million.
Strongly committed, prestigious founders and shareholders: Airbus Group (Matra Défense), Professor Alain Carpentier, the Centre Chirurgical Marie Lannelongue, Truffle Capital, a leading European venture capital firm, ALIAD, Air Liquide’s venture capital investor, CorNovum, an investment holding company held 50-50 by Bpifrance and the French State, the family offices of Pierre Bastid (ZAKA) and of Dr. Antonino Ligresti (Santé Holdings S.R.L.) as well as the thousands of institutional and individual shareholders who have placed their trust in CARMAT.
For more information: www.carmatsa.com
This prestigious award is attributed by the European Patent Office (EPO) to scientists, researchers and engineers whose EPO-patented inventions have contributed to technological progress, social development and economic growth. 15 finalists have been shortlisted by an independent international jury from almost 400 inventors from 13 countries. Professor Carpentier is one of 3 finalists in the Lifetime Achievement category, and has been nominated for his work on the CARMAT artificial heart.
“We are delighted with this nomination for Professor Carpentier and for CARMAT. It again illustrates the Professor’s impressive scientific career and the amazing potential of the CARMAT prosthesis for patients suffering from end-stage heart failure, and highlights the Company’s economic development prospects in Europe and around the world”, says Jean-Claude Cadudal, Chairman of CARMAT.
About CARMAT: the world’s most advanced total artificial heart project
A credible response to end-stage heart failure: CARMAT aims to eventually provide a response to a major public health issue associated with heart disease, the world’s leading cause of death: chronic and acute heart failure. By pursuing the development of its total artificial heart, CARMAT intends to overcome the well-known shortfall in heart transplants for the tens of thousands of people suffering from irreversible end-stage heart failure, the most seriously affected of the 20 million patients with this progressive disease in Europe and the United States.
The result of combining two types of unique expertise: the medical expertise of Professor Carpentier, known throughout the world for inventing Carpentier-Edwards® heart valves, which are the most used in the world, and the technological expertise of Airbus Group, world aerospace leader.
Imitating the natural heart: given its size, the choice of structural materials and its innovative physiological functions, CARMAT’s total artificial heart could, assuming the necessary clinical trials are successful, potentially benefit the lives of thousands of patients a year with no risk of rejection and with a good quality of life.
A project leader acknowledged at a European level: with the backing of the European Commission, CARMAT has been granted the largest subsidy ever given to an SME by Bpifrance; a total of €33 million.
Strongly committed, prestigious founders and shareholders: Airbus Group (Matra Défense), Professor Alain Carpentier, the Centre Chirurgical Marie Lannelongue, Truffle Capital, a leading European venture capital firm, ALIAD, Air Liquide’s venture capital investor, CorNovum, an investment holding company held 50-50 by Bpifrance and the French State, the family offices of Pierre Bastid (ZAKA) and of Dr. Antonino Ligresti (Santé Holdings S.R.L.) as well as the thousands of institutional and individual shareholders who have placed their trust in CARMAT.
For more information: www.carmatsa.com